These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28721372)

  • 1. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in
    Tung N; Garber JE; Hacker MR; Torous V; Freeman GJ; Poles E; Rodig S; Alexander B; Lee L; Collins LC; Schnitt SJ
    NPJ Breast Cancer; 2016; 2():16002. PubMed ID: 28721372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
    Bae SB; Cho HD; Oh MH; Lee JH; Jang SH; Hong SA; Cho J; Kim SY; Han SW; Lee JE; Kim HJ; Lee HJ
    J Breast Cancer; 2016 Sep; 19(3):242-251. PubMed ID: 27721873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
    Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
    Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
    Monneur A; Gonçalves A; Bertucci F
    Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    Patel JM; Goss A; Garber JE; Torous V; Richardson ET; Haviland MJ; Hacker MR; Freeman GJ; Nalven T; Alexander B; Lee L; Collins LC; Schnitt SJ; Tung N
    NPJ Breast Cancer; 2020; 6():19. PubMed ID: 32550264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    Guiu S; Mollevi C; Charon-Barra C; Boissière F; Crapez E; Chartron E; Lamy PJ; Gutowski M; Bourgier C; Romieu G; Simony-Lafontaine J; Jacot W
    Br J Cancer; 2018 Jul; 119(1):76-79. PubMed ID: 29880907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 in breast cancer: comparative analysis of 3 different antibodies.
    Karnik T; Kimler BF; Fan F; Tawfik O
    Hum Pathol; 2018 Feb; 72():28-34. PubMed ID: 28843709
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Jacot W; Lopez-Crapez E; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Ho-Pun-Cheung A; Chartron E; Theillet C; Lemoine A; Saffroy R; Lamy PJ; Guiu S
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.